Latest Abbott Stories

ABBOTT PARK, Ill., May 22, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will participate in the Deutsche Bank 38(th) Annual Health Care Conference on Wednesday, May 29, 2013. Thomas C. Freyman, executive vice president, finance and chief financial officer, and Scott White, senior vice president, international nutrition, will present at 1:10 p.m. Central time. A live audio webcast will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com. An archived...

- XIENCE Xpedition(TM) 48 Leverages Proven Design and Clinical Outcomes of the XIENCE Family of Drug Eluting Stents ABBOTT PARK, Ill., May 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition(TM) 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the proven design and...

Allegheny General Hospital (AGH) in Pittsburgh has been selected to join the ABSORB III clinical trial, a multi-center international study exploring a unique bioresorbable vascular scaffold (BVS), a small mesh tube that is designed to open a blocked artery and then fully dissolve over time, leaving the vessel free of a permanent metallic implant. The FDA-approved study of the drug-eluting AbsorbTM BVS, made by healthcare company Abbott, is expected to enroll approximately 2,250 patients...

ABBOTT PARK, Ill., May 8, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2013. Thomas C. Freyman, executive vice president, finance and chief financial officer, and Brian Blaser, executive vice president, diagnostics products, will present at 7:30 a.m. Central time. A live audio webcast will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com. An archived edition of the...

CAMBRIDGE, Mass., April 18, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has signed an agreement with Abbott, a global healthcare company, to develop a molecular companion diagnostic test for use with EPZ-5676. EPZ-5676, Epizyme's most advanced clinical product candidate, is an inhibitor targeting the DOT1L histone...

ABBOTT PARK, Ill., April 18, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the TECNIS(®) Toric 1-Piece intraocular lens (IOL) has received U.S. Food and Drug Administration (FDA) approval and is launching in the United States for the treatment of cataract patients with pre-existing corneal astigmatism. Corneal astigmatism is a condition where the curvature of the cornea is uneven, preventing light rays from focusing clearly on the retina, resulting in blurred...

ABBOTT PARK, Ill., April 1, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2013 financial results on Wednesday, April 17, 2013, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time. About...

ABBOTT PARK, Ill., March 20, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of treatment with the MitraClip(®) device outweigh its risks in patients with significant symptomatic mitral regurgitation (MR) who have been determined by a cardiac surgeon to be too high risk for open mitral valve...

-- Three-year clinical results for treating clogged vessels in the heart with Absorb presented at American College of Cardiology 2013 SAN FRANCISCO, March 11, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive long-term results for the company's innovative Absorb(TM) Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial were presented at the 62nd Annual Scientific Session of the American College of...

SAN FRANCISCO, March 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip(®) System for the treatment of mitral regurgitation (MR). Findings were presented today at the 62nd Annual Scientific Session of the American College of Cardiology in San Francisco. Abbott's MitraClip system, an investigational device in the...